Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis
Document Type
Article
Publication Date
1-1-2022
Subject Area
Male; Humans; Aged; United States (epidemiology); Metformin (therapeutic use); Diabetes Mellitus, Type 2 (complications); Hypoglycemic Agents (therapeutic use); Cohort Studies; Retrospective Studies; Medicare; Pancreatic Neoplasms (drug therapy)
Abstract
Cancer is a major health problem in the U.S and type 2 diabetes mellitus (T2DM) is known to increase the risk for the development of many cancers. Metformin, a first-line therapy for treating T2DM, is increasingly being used for its anticancer effects; however, the literature is limited on the effect of metformin dose on overall survival in patients with stage IV cancer. Overall survival was defined as the time interval from the date of diagnosis to the last known follow-up or death from any cause. Subjects who were alive on December 31, 2016 were censored. In this cohort study we examined the relationship between metformin dose and overall survival in persons with both T2DM and stage IV lung, breast, colorectal, prostate, or pancreas cancers. We used a retrospective study design with Cox proportional hazards regression analysis of the 2007-2016 of the Surveillance Epidemiology and End Results-Medicare (SEER) dataset. Of the 7,725 patients, 2,981(38.5%) had been prescribed metformin. Patients who used metformin had significantly better overall survival in both unadjusted (Unadjusted HR, 0.73; 95% CI, 0.69-0.76; p < 0.001) and adjusted models (adjusted HR, 0.77; 95% CI, 0.73-0.81; p < 0.001). The overall survival between patients who took metformin with average daily dose ≥ 1000mg or < 1000mg were not statistically significant (aHR, 1.00; 95% CI, 0.93-1.08; p = 0.90). Metformin use regardless of dose is associated with increased overall survival in older adults with stage IV cancer.
Publication Title
PloS one
Volume
17
Issue
10
First Page
e0275681
Digital Object Identifier (DOI)
10.1371/journal.pone.0275681
PubMed ID
36260549
E-ISSN
1932-6203
Language
eng
Citation Information
Scarton, Lisa; Jo, Ara; Xie, Zhigang; O'Neal, LaToya J.; Munoz Pena, Juan M.; George, Thomas J.; and Bian, Jiang, "Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis" (2022). UNF Faculty Research and Scholarship. 3170.
https://digitalcommons.unf.edu/unf_faculty_publications/3170